share_log

Canaccord Genuity Initiates Coverage On Apogee Therapeutics With Buy Rating, Announces Price Target of $89

Canaccord Genuity Initiates Coverage On Apogee Therapeutics With Buy Rating, Announces Price Target of $89

Canaccord Genuity對Apogee Therapeutics啓動了覆蓋,給予買入評級,並宣佈目標價格爲89美元。
Benzinga ·  11/25 19:21  · 評級/大行評級

Canaccord Genuity analyst Edward Nash initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Buy rating and announces Price Target of $89.

Canaccord Genuity 分析師愛德華·納什開始對Apogee Therapeutics(納斯達克:APGE)進行評級,給予買入評級,並宣佈目標價爲89美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論